Risk-reducing surgery in women at risk for familial breast or ovarian cancer;Prophylaktische Operationen bei familiärem Mamma- und Ovarialkarzinomrisiko

Geburtshilfe und Frauenheilkunde

Volumn 72, Issue 9, 2012, Pages 833-839

  Rhiem, K ^a   Pfeifer, K ^b   Schmutzler, R K ^a   Kiechle, M ^b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

BRCA; breast; breast cancer; genetics; gynaecology; ovary

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ALLELE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENETIC COUNSELING; HIGH RISK PATIENT; HUMAN; MASTECTOMY; MORTALITY; OVARY CANCER; PROPHYLACTIC MASTECTOMY; PROPHYLACTIC SALPINGOOOPHORECTOMY; REVIEW; RISK REDUCTION; SALPINGOOOPHORECTOMY;

EID: 84866527142     PISSN: 00165751     EISSN: 14388804     Source Type: Journal    
DOI: 10.1055/s-0032-1315362     Document Type: Review

References (23)

1. Robert Koch-Institut, Zentrum für Krebsregisterdaten http://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Brustkrebs/brustkrebs-node. html Stand: 23.08.2012
2. http://www.krebsgesellschaft.de/download/fb-erbliche-belastung-110106.xls Stand: 23.08.2012
3. Meindl A., Ditsch N., Kast K. et al. Hereditary breast and ovarian cancer-new genes, new treatments, new concepts. Dtsch Arztebl Int: 2011; 108 323 330, 10.3238/arztebl.2011.0323
4. Meindl A., Hellebrand H., Wiek C. et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD 51C as a human cancer susceptibility gene. Nat Genet: 2010; 42 410 414
5. Soegaard M., Kjær S. K., Cox M. et al. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. Clin Cancer Res: 2008; 14 3761 3767
6. Lakhani S. R., Manek S., Penault-Llorca F. et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res: 2004; 10 2473 2481 (Pubitemid 38445709)
7. Chetrit A., Hirsh-Yechezkel G., Ben-David Y. et al. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol: 2008; 26 20 25
8. Cass I., Baldwin R. L., Varkey T. et al. Improved survival in women with BRCA associated ovarian carcinoma. Cancer: 2003; 97 2187 2195 (Pubitemid 36444059)
9. Bolton K. L., Chevenvix-Trench G., Goh C. et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive enpithelial ovarian cancer. JAMA: 2012; 307 382 390
10. Foulkes W. D., Stefansson I. M., Chappuis P. O. et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst: 2003; 95 1482 1485 (Pubitemid 37279334)
11. Lakhani S. R., Reis-Filho J. S., Fulford L. et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res: 2005; 11 5175 5180 (Pubitemid 41003703)
12. Robson M. E., Chappuis P. O., Satagopan J. et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res: 2004; 6 R8 R17
13. Graeser M. K., Engel C., Rhiem K. et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol: 2009; 27 1 6
14. Rhiem K., Engel C., Graeser M. et al. The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1- or BRCA2 positive families: a retrospective cohort study. Breast Cancer Res [in press]
15. Metcalfe K., Lynch H. T., Ghadirian P. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol: 2004; 22 2328 2335 (Pubitemid 41115389)
16. Albert U. Stufe-3-Leitlinie Früherkennung, Diagnostik und Therapie des Mammakarzinoms. München Zuckschwerdt: 2008
17. Bosse K., Rhiem K., Wappenschmidt B. et al. Screening for ovarian cancer by trans-vaginal ultrasound and serum CA125 measurement in women with familial pre-disposition; a prospective cohort study. Gynecol Oncol: 2006; 1033 1077 1082 (Pubitemid 44821336)
18. Meijers-Heijboer H., van Geel B., van Putten W. L. et al. Breast cancer after prophylactic bilateral mastectomy in women with BRCA1 and BRCA2 mutation. N Engl J Med: 2001; 345 159 164 (Pubitemid 32662123)
19. Rebbeck T. R., Friebel T., Lynch H. T. The PROSE Study Group Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol: 2004; 22 1055 1062 (Pubitemid 41095038)
20. Domchek S. M., Friebel T. M., Neuhausen S. L. et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet: 2006; 7 223 229 (Pubitemid 43286452)
21. Kauff N. D., Satagopan J. M., Robson M. E. et al. Risk reducing salpingo-oophorectomy in women with BRCA1 and BRCA2 mutation. N Engl J Med: 2002; 346 1609 1615 (Pubitemid 34755668)
22. Kauff N. D., Domchek S. M., Friebel T. M. et al. Risk reducing salpino-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective Study. J Clin Oncol: 2008; 26 1331 1337
23. Pierce L. J., Levin A. M., Rebbeck T. R. et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol (United States): 2006; 24 2437 2443 (Pubitemid 46630619)